| Variables |
PD with pRBD (n=13) |
PD with confirmed RBD on PSG (n=7) |
PD non-RBD (n=16) |
| Age, years |
65.5 |
64 |
64.6 |
| Females, n (%) |
5 (38.5) |
3 (42.9) |
7 (43.8) |
| Disease duration, years |
2.2 (1-5) |
2.2 (1-5) |
2.9 (0.5-6) |
| MMSE score |
28.9 (26-30) |
29 (26-30) |
29 (26-30) |
| UPDRS part III motor subscale score |
11.8 (6-26) |
10.1 (6-17) |
14.7 (3-31) |
| Hoehn and Yahr stage (1/1.5/2/2.5), n |
5/4/3/1 |
2/2/2/1 |
5/3/4/4 |
| GDS stage 1/2/3, n |
7/3/2003 |
3/1/2003 |
8/3/2005 |
| MCI n % |
3 (23.1) |
3(42.9) |
5(31.3) |
| Education, years |
12.3 (7-18) |
11.7 (6-17) |
12.7 (8-19) |
| NMSS |
9.7 (4-7) |
10.4 (6-17) |
7.1*(4-18) |
| Geriatric depression scale |
1.6 (0-4) |
1.1 (0-3) |
1.1 (0-3) |
| L Dopa Equivalent Dosage |
287.5 (100-662) |
369.6 (100-662) |
403 (100-662) |
|
| Table 1: Baseline characteristics, Numbers represent mean (range) or
number of patients (%), *p<05 (pRBD vs non-RBD), t-test, PSG:
Polysomnography, MMSE: Mini-mental state examination, GDS:
Global deterioration scale 1 (normal), 2 (Subjective cognitive
impairment) and 3 (mild cognitive impairment), NMSS: Non-motor
symptom scale. Standardized rating scales of motor function [9]
(UPDRS part III, motor sub-scale) and Hoehn and Yahr staging [10]
were performed by trained research physicians. Drug use was
recorded, and L-DOPA equivalents calculated [11]. |
